Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector - PubMed (original) (raw)
Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector
W K O'Neal et al. Mol Med. 2000 Mar.
Abstract
Background: Certain gene therapy protocols may require multiple administrations of vectors to achieve therapeutic benefit to the patient. This may be especially relevant for vectors such as adenoviral vectors that do not integrate into the host chromosome. Because immunocompetent animal models used for gene transfer studies develop neutralizing antibodies to adenoviral vectors after a single administration, little is known about how repeat administrations of vectors might affect transgene expression and vector toxicity.
Materials and methods: We used mice deficient in the membrane spanning region of immunoglobulin (IgM), which do not develop antibodies, to evaluate the effect of repeated intravenous administration of first-generation and helper-dependent adenoviral vectors expressing human alpha 1-antitrypsin (hAAT). The duration and levels of transgene expression were evaluated after repeated administration of vectors. Toxicity was assessed by measuring the level of liver enzymes in the serum and the degrees of hepatocyte hypertrophy and proliferation.
Results: We found that previous administration of first-generation adenoviral vectors can alter the response to subsequent doses. These alterations included an increase in transgene expression early (within 1 and 3 days), followed by a rapid drop in expression by day 7. In addition, previous administrations of first-generation vectors led to an increase in toxicity of subsequent doses, as indicated by a rise in liver enzymes and an increase in hepatocyte proliferation. In contrast to first-generation vectors, use of the helper-dependent adenovirus vector, Ad-STK109, which contained no viral coding regions, did not lead to increased toxicity after multiple administrations.
Conclusions: We conclude that the response of the host to adenoviral vectors can be altered after repeated administration, compared with the response after the initial vector dose. In addition, these experiments provide further evidence for the relative safety of helper-dependent adenoviral vectors for gene therapy, compared with first-generation vectors.
Similar articles
- Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.
Morral N, O'Neal W, Rice K, Leland M, Kaplan J, Piedra PA, Zhou H, Parks RJ, Velji R, Aguilar-Córdova E, Wadsworth S, Graham FL, Kochanek S, Carey KD, Beaudet AL. Morral N, et al. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12816-21. doi: 10.1073/pnas.96.22.12816. Proc Natl Acad Sci U S A. 1999. PMID: 10536005 Free PMC article. - Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors.
Pastore L, Morral N, Zhou H, Garcia R, Parks RJ, Kochanek S, Graham FL, Lee B, Beaudet AL. Pastore L, et al. Hum Gene Ther. 1999 Jul 20;10(11):1773-81. doi: 10.1089/10430349950017455. Hum Gene Ther. 1999. PMID: 10446917 - Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.
Morral N, O'Neal W, Zhou H, Langston C, Beaudet A. Morral N, et al. Hum Gene Ther. 1997 Jul 1;8(10):1275-86. doi: 10.1089/hum.1997.8.10-1275. Hum Gene Ther. 1997. PMID: 9215744 - Helper-dependent adenoviral vectors for gene therapy.
Palmer DJ, Ng P. Palmer DJ, et al. Hum Gene Ther. 2005 Jan;16(1):1-16. doi: 10.1089/hum.2005.16.1. Hum Gene Ther. 2005. PMID: 15703484 Review. - Advances in helper-dependent adenoviral vector research.
Segura MM, Alba R, Bosch A, Chillón M. Segura MM, et al. Curr Gene Ther. 2008 Aug;8(4):222-35. doi: 10.2174/156652308785160647. Curr Gene Ther. 2008. PMID: 18691018 Review.
Cited by
- Gene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art.
Amato A, Arrigo A, Aragona E, Manitto MP, Saladino A, Bandello F, Battaglia Parodi M. Amato A, et al. Front Med (Lausanne). 2021 Oct 15;8:750586. doi: 10.3389/fmed.2021.750586. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34722588 Free PMC article. Review. - High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy.
Ricobaraza A, Gonzalez-Aparicio M, Mora-Jimenez L, Lumbreras S, Hernandez-Alcoceba R. Ricobaraza A, et al. Int J Mol Sci. 2020 May 21;21(10):3643. doi: 10.3390/ijms21103643. Int J Mol Sci. 2020. PMID: 32455640 Free PMC article. Review. - Current development in adenoviral vectors for cancer immunotherapy.
Biegert GWG, Rosewell Shaw A, Suzuki M. Biegert GWG, et al. Mol Ther Oncolytics. 2021 Nov 20;23:571-581. doi: 10.1016/j.omto.2021.11.014. eCollection 2021 Dec 17. Mol Ther Oncolytics. 2021. PMID: 34938857 Free PMC article. Review. - Preventive Effect of a Synbiotic Combination of Galacto- and Fructooligosaccharides Mixture With Bifidobacterium breve M-16V in a Model of Multiple Rotavirus Infections.
Rigo-Adrover MDM, van Limpt K, Knipping K, Garssen J, Knol J, Costabile A, Franch À, Castell M, Pérez-Cano FJ. Rigo-Adrover MDM, et al. Front Immunol. 2018 Jun 11;9:1318. doi: 10.3389/fimmu.2018.01318. eCollection 2018. Front Immunol. 2018. PMID: 29942312 Free PMC article. - Gene therapy for cystic fibrosis: new tools for precision medicine.
Lee JA, Cho A, Huang EN, Xu Y, Quach H, Hu J, Wong AP. Lee JA, et al. J Transl Med. 2021 Oct 30;19(1):452. doi: 10.1186/s12967-021-03099-4. J Transl Med. 2021. PMID: 34717671 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical